Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

WuXi Biologics Licenses Clinical‑Stage T‑Cell Engager to Zai Lab for Solid Tumor Development

Fineline Cube Jan 15, 2026
Company Deals

WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership

Fineline Cube Jan 15, 2026
Company Deals

Fosun Kairos Secures Greater China Rights to ElpasBio’s AlloJoin for Knee Osteoarthritis

Fineline Cube Jan 15, 2026
Company Deals

Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB 1.2 B, Adding siRNA Platform for Chronic Diseases

Fineline Cube Jan 15, 2026
Company Deals

Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011

Fineline Cube Jan 15, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma

Fineline Cube Jan 15, 2026
Company Drug

Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific

Fineline Cube Jan 15, 2026
Company Drug

Haisco Pharmaceutical’s HSK46575 Receives NMPA Approval for Prostate Cancer Clinical Trial

Fineline Cube Dec 5, 2024

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced the receipt of clinical trial...

Company Drug

Sichuan Kelun-Biotech’s SKB500 Receives NMPA Clinical Clearance for Solid Tumor Treatment

Fineline Cube Dec 5, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd, (HKG: 6990), a leading biopharmaceutical company based in China, has...

Company Drug

Cinclus Pharma’s Linaprazan for GERD Receives NMPA Marketing Approval

Fineline Cube Dec 5, 2024

Sweden-based Cinclus Pharma has announced that it has received marketing approval from the National Medical...

Company

CSPC Pharmaceutical’s CRB-701 Earns FDA Fast Track Designation for Cervical Cancer Treatment

Fineline Cube Dec 5, 2024

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has announced that it has received Fast...

Company Medical Device

Sisram Medical’s Alma Harmony and Alma Hybrid Receive EU Medical Device Certification

Fineline Cube Dec 5, 2024

Sisram Medical Ltd (HKG: 1696), an Israel-based company and part of the Fosun Pharmaceutical Group...

Company Drug

Shanghai Henlius Biotech’s HLX11 Biosimilar Accepted for Review by China’s CDE

Fineline Cube Dec 5, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a leading biopharmaceutical company based in China, has announced...

Company Deals

Wuhan Kaideweisi Biotechnology Secures Series B Funding for Gynecologic Oncology Expansion

Fineline Cube Dec 5, 2024

Wuhan Kaideweisi Biotechnology Co., Ltd, a specialist in gynecologic oncology in China, has reportedly raised...

Company Drug

Shanghai Henlius Biotech’s HLX22 Receives NMPA Approval for Phase II HER2-Targeted Study

Fineline Cube Dec 5, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...

Company Deals

Jiangsu Recbio Technology Secures Private Placement with Yangtze River Pharmaceutical for Vaccine Development

Fineline Cube Dec 5, 2024

China-based Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has successfully placed 142 million shares through...

Company Deals

Hangzhou Chance Pharmaceuticals Partners with Yiling Pharmaceutical for Inhalation Powder Development

Fineline Cube Dec 5, 2024

China’s Hangzhou Chance Pharmaceuticals Co., Ltd., a specialist in lung drug delivery, has entered into...

Company Deals

GRIT Biotechnology and Vitalgen BioPharma Partner on CRISPR-AaCas12bMAX Cell Therapies

Fineline Cube Dec 5, 2024

China-based cell therapy specialists GRIT Biotechnology and Shanghai Vitalgen BioPharma Co., Ltd have entered into...

Company Deals

YiChang HEC ChangJiang Pharmaceutical and DP Technology Deepen Partnership with AI Focus

Fineline Cube Dec 5, 2024

China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced a comprehensive partnership with...

Company Deals

Mabwell Bioscience Enters Licensing Agreement for Biosimilar Denosumab in Peru

Fineline Cube Dec 5, 2024

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a licensing agreement with its...

Company Deals

Analytical BioSciences Sells Global Rights to Pre-Clinical Anti-Tumor Drugs to Gilead

Fineline Cube Dec 4, 2024

Sino-US firm Analytical BioSciences Limited has entered into an asset purchase agreement with Gilead (NASDAQ:...

Company Deals

CanSino Biologics Partners with Etana for Inhaled Tuberculosis Vaccine Development

Fineline Cube Dec 4, 2024

China-based CanSino Biologics (SHA: 688185, HKG: 6185) has entered into a strategic partnership with Indonesia-based...

Company Deals

Zhida Pharma Secures Licensing Deal for Vivesto AB’s Apealea in China

Fineline Cube Dec 4, 2024

Zhejiang-based Zhida Pharma has announced a licensing deal with Sweden-headquartered Vivesto AB (STO: VIVE), securing...

Company Deals

Guangzhou Innogen Pharmaceutical Files for IPO on Hong Kong Stock Exchange

Fineline Cube Dec 4, 2024

Guangzhou Innogen Pharmaceutical Group Co., Ltd., a China-based pharmaceutical company, has made an initial public...

Company Deals

Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals in Asset Purchase Deal

Fineline Cube Dec 4, 2024

US-based Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) has announced an asset purchase agreement with Indian-headquartered...

Company Deals Drug

GSK plc Enters Exclusive Option Agreement with Duality Biologics for ADC Candidate DB-1324

Fineline Cube Dec 4, 2024

UK-based GSK plc (NYSE: GSK) has entered into an exclusive option agreement with Duality Biologics,...

Company Deals

Keros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development

Fineline Cube Dec 4, 2024

US-based Keros Therapeutics, Inc. (NASDAQ: KROS) has announced a significant licensing agreement with Japan-headquartered Takeda...

Posts pagination

1 … 197 198 199 … 610

Recent updates

  • WuXi Biologics Licenses Clinical‑Stage T‑Cell Engager to Zai Lab for Solid Tumor Development
  • ABM Therapeutics Licenses MEK1/2 Inhibitor ABM‑168 to Mosaica Medicines for Global Development
  • WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership
  • Fosun Kairos Secures Greater China Rights to ElpasBio’s AlloJoin for Knee Osteoarthritis
  • Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB 1.2 B, Adding siRNA Platform for Chronic Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

WuXi Biologics Licenses Clinical‑Stage T‑Cell Engager to Zai Lab for Solid Tumor Development

Company Digital

ABM Therapeutics Licenses MEK1/2 Inhibitor ABM‑168 to Mosaica Medicines for Global Development

Company Deals

WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership

Company Deals

Fosun Kairos Secures Greater China Rights to ElpasBio’s AlloJoin for Knee Osteoarthritis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.